Science
Science is a clinical-stage medical technology company focused on developing neural interface systems to address conditions such as vision loss, cognitive impairment, and motor dysfunction. The company integrates neural recording electronics, optogenetic stimulation, and software platforms to create brain-computer interface (BCI) solutions. Its product suite includes Axon neural probes, the SciFi headstage, and the Synapse communication protocol, which together form a modular platform for neural engineering applications. Science also develops implantable devices like PRIMA, a wireless photovoltaic stimulation array aimed at restoring vision in patients with retinal degenerative diseases.
| Round | Announced | Raised | Post-money |
|---|---|---|---|
| Series C | Mar 5, 2026 | $230M | $1.5B |
| Series C | Apr 14, 2025 | $121.6M | $862.7M |
| Series A | Jan 1, 2025 | $35.7M | $511.9M |
| Series A | May 23, 2024 | $26M | $305.1M |
| Series A | Jul 6, 2021 | $47.3M | $236.6M |
- KVKhosla Ventures
- LVLightspeed Venture Partners
- IQIQT
- QCQuiet Capital
- CCConversion Capital
- FYFifty Years
- HCHOF Capital
- YCY Combinator
- AVArtis Ventures
- PLProtocol Labs
Invest in the private markets on Legion
Registered users see full trading activity, every investor, rankings, and live deals.
Data as of .
